{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:22:56Z","timestamp":1791418976080,"version":"4.3.3"},"reference-count":88,"publisher":"National Institute for Health and Care Research","issue":"39","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["15\/35\/03"],"award-info":[{"award-number":["15\/35\/03"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n The mainstay of treatment for diabetic peripheral neuropathic pain is pharmacotherapy, but the current National Institute for Health and Care Excellence guideline is not based on robust evidence, as the treatments and their combinations have not been directly compared.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To determine the most clinically beneficial, cost-effective and tolerated treatment pathway for diabetic peripheral neuropathic pain.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n A randomised crossover trial with health economic analysis.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n Twenty-one secondary care centres in the UK.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Adults with diabetic peripheral neuropathic pain with a 7-day average self-rated pain score of \u2265\u20094 points (Numeric Rating Scale 0\u201310).<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomised to three commonly used treatment pathways: (1) amitriptyline supplemented with pregabalin, (2) duloxetine supplemented with pregabalin and (3) pregabalin supplemented with amitriptyline. Participants and research teams were blinded to treatment allocation, using over-encapsulated capsules and matching placebos. Site pharmacists were unblinded.<\/jats:p>\n <\/jats:sec>\n \n Outcomes<\/jats:title>\n The primary outcome was the difference in 7-day average 24-hour Numeric Rating Scale score between pathways, measured during the final week of each pathway. Secondary end points included 7-day average daily Numeric Rating Scale pain score at week 6 between monotherapies, quality of life (Short Form questionnaire-36 items), Hospital Anxiety and Depression Scale score, the proportion of patients achieving 30% and 50% pain reduction, Brief Pain Inventory \u2013 Modified Short Form items scores, Insomnia Severity Index score, Neuropathic Pain Symptom Inventory score, tolerability (scale 0\u201310), Patient Global Impression of Change score at week 16 and patients\u2019 preferred treatment pathway at week 50. Adverse events and serious adverse events were recorded. A within-trial cost\u2013utility analysis was carried out to compare treatment pathways using incremental costs per quality-adjusted life-years from an NHS and social care perspective.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 140 participants were randomised from 13 UK centres, 130 of whom were included in the analyses. Pain score at week 16 was similar between the arms, with a mean difference of \u20130.1 points (98.3% confidence interval \u20130.5 to 0.3 points) for duloxetine supplemented with pregabalin compared with amitriptyline supplemented with pregabalin, a mean difference of \u20130.1 points (98.3% confidence interval \u20130.5 to 0.3 points) for pregabalin supplemented with amitriptyline compared with amitriptyline supplemented with pregabalin and a mean difference of 0.0 points (98.3% confidence interval \u20130.4 to 0.4 points) for pregabalin supplemented with amitriptyline compared with duloxetine supplemented with pregabalin. Results for tolerability, discontinuation and quality of life were similar. The adverse events were predictable for each drug. Combination therapy (weeks 6\u201316) was associated with a further reduction in Numeric Rating Scale pain score (mean 1.0 points, 98.3% confidence interval 0.6 to 1.3 points) compared with those who remained on monotherapy (mean 0.2 points, 98.3% confidence interval \u20130.1 to 0.5 points). The pregabalin supplemented with amitriptyline pathway had the fewest monotherapy discontinuations due to treatment-emergent adverse events and was most commonly preferred (most commonly preferred by participants: amitriptyline supplemented with pregabalin, 24%; duloxetine supplemented with pregabalin, 33%; pregabalin supplemented with amitriptyline, 43%;\n p<\/jats:italic>\n \u2009=\u20090.26). No single pathway was superior in cost-effectiveness. The incremental gains in quality-adjusted life-years were small for each pathway comparison [amitriptyline supplemented with pregabalin compared with duloxetine supplemented with pregabalin \u20130.002 (95% confidence interval \u20130.011 to 0.007) quality-adjusted life-years, amitriptyline supplemented with pregabalin compared with pregabalin supplemented with amitriptyline \u20130.006 (95% confidence interval \u20130.002 to 0.014) quality-adjusted life-years and duloxetine supplemented with pregabalin compared with pregabalin supplemented with amitriptyline 0.007 (95% confidence interval 0.0002 to 0.015) quality-adjusted life-years] and incremental costs over 16 weeks were similar [amitriptyline supplemented with pregabalin compared with duloxetine supplemented with pregabalin \u2212\u00a3113 (95% confidence interval \u2212\u00a3381 to \u00a390), amitriptyline supplemented with pregabalin compared with pregabalin supplemented with amitriptyline \u00a3155 (95% confidence interval \u2212\u00a337 to \u00a3625) and duloxetine supplemented with pregabalin compared with pregabalin supplemented with amitriptyline \u00a3141 (95% confidence interval \u2212\u00a313 to \u00a3398)].\n <\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Although there was no placebo arm, there is strong evidence for the use of each study medication from randomised placebo-controlled trials. The addition of a placebo arm would have increased the duration of this already long and demanding trial and it was not felt to be ethically justifiable.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n Future research should explore (1) variations in diabetic peripheral neuropathic pain management at the practice level, (2) how OPTION-DM (Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus) trial findings can be best implemented, (3) why some patients respond to a particular drug and others do not and (4) what options there are for further treatments for those patients on combination treatment with inadequate pain relief.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The three treatment pathways appear to give comparable patient outcomes at similar costs, suggesting that the optimal treatment may depend on patients\u2019 preference in terms of side effects.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n The trial is registered as ISRCTN17545443 and EudraCT 2016-003146-89.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n \n This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme, and will be published in full in\n Health Technology Assessment<\/jats:italic>\n ; Vol. 26, No. 39. See the NIHR Journals Library website for further project information.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/rxuo6757","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T08:29:30Z","timestamp":1666168170000},"page":"1-100","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT"],"prefix":"10.3310","volume":"26","clinical-trial-number":[{"clinical-trial-number":"isrctn17545443","registry":"10.18810\/isrctn","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1190-1472","authenticated-orcid":true,"given":"Solomon","family":"Tesfaye","sequence":"first","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"},{"name":"Department of Oncology and Human Metabolism, Medical School, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6164-2662","authenticated-orcid":true,"given":"Gordon","family":"Sloan","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-6724","authenticated-orcid":true,"given":"Jennifer","family":"Petrie","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2871-7946","authenticated-orcid":true,"given":"David","family":"White","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-9761","authenticated-orcid":true,"given":"Mike","family":"Bradburn","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-0471","authenticated-orcid":true,"given":"Tracey","family":"Young","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3995-5336","authenticated-orcid":true,"given":"Satyan","family":"Rajbhandari","sequence":"additional","affiliation":[{"name":"Lancashire Teaching Hospitals NHS Trust, Chorley, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6386-2052","authenticated-orcid":true,"given":"Sanjeev","family":"Sharma","sequence":"additional","affiliation":[{"name":"East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3331-7015","authenticated-orcid":true,"given":"Gerry","family":"Rayman","sequence":"additional","affiliation":[{"name":"East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5852-470X","authenticated-orcid":true,"given":"Ravikanth","family":"Gouni","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-1122","authenticated-orcid":true,"given":"Uazman","family":"Alam","sequence":"additional","affiliation":[{"name":"University of Liverpool, Liverpool, UK"},{"name":"Liverpool University Hospital NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9917-7636","authenticated-orcid":true,"given":"Steven A","family":"Julious","sequence":"additional","affiliation":[{"name":"Medical Statistics Group, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2995-5447","authenticated-orcid":true,"given":"Cindy","family":"Cooper","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7089-1580","authenticated-orcid":true,"given":"Amanda","family":"Loban","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5162-8119","authenticated-orcid":true,"given":"Katie","family":"Sutherland","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2460-3354","authenticated-orcid":true,"given":"Rachel","family":"Glover","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6303-9610","authenticated-orcid":true,"given":"Simon","family":"Waterhouse","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5763-9604","authenticated-orcid":true,"given":"Emily","family":"Turton","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3069-6091","authenticated-orcid":true,"given":"Michelle","family":"Horspool","sequence":"additional","affiliation":[{"name":"NHS Sheffield Clinical Commissioning Group, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2008-2301","authenticated-orcid":true,"given":"Rajiv","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-0997","authenticated-orcid":true,"given":"Deirdre","family":"Maguire","sequence":"additional","affiliation":[{"name":"Harrogate and District NHS Foundation Trust, Harrogate, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3186-4122","authenticated-orcid":true,"given":"Edward","family":"Jude","sequence":"additional","affiliation":[{"name":"Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton under Lyne, UK"},{"name":"University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-2907","authenticated-orcid":true,"given":"Syed Haris","family":"Ahmed","sequence":"additional","affiliation":[{"name":"University of Liverpool, Liverpool, UK"},{"name":"Countess of Chester Hospital NHS Foundation Trust, Chester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7448-2995","authenticated-orcid":true,"given":"Prashanth","family":"Vas","sequence":"additional","affiliation":[{"name":"King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-5807","authenticated-orcid":true,"given":"Christian","family":"Hariman","sequence":"additional","affiliation":[{"name":"Royal Wolverhampton NHS Trust, Wolverhampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-5267","authenticated-orcid":true,"given":"Claire","family":"McDougall","sequence":"additional","affiliation":[{"name":"University Hospital Hairmyres, East Kilbride, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2605-4093","authenticated-orcid":true,"given":"Marion","family":"Devers","sequence":"additional","affiliation":[{"name":"University Hospital Monklands, Airdrie, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9413-5130","authenticated-orcid":true,"given":"Vasileios","family":"Tsatlidis","sequence":"additional","affiliation":[{"name":"Gateshead Health NHS Foundation Trust, Gateshead, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8398-5436","authenticated-orcid":true,"given":"Martin","family":"Johnson","sequence":"additional","affiliation":[{"name":"hVIVO Services Limited, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6446-8719","authenticated-orcid":true,"given":"Didier","family":"Bouhassira","sequence":"additional","affiliation":[{"name":"Hospital Ambroise Par\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7996-2696","authenticated-orcid":true,"given":"David L","family":"Bennett","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7426-1105","authenticated-orcid":true,"given":"Dinesh","family":"Selvarajah","sequence":"additional","affiliation":[{"name":"Department of Oncology and Human Metabolism, Medical School, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2022,10]]},"reference":[{"key":"key20221018113808326_ref1-bib1","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0140-6736(22)01472-6","article-title":"Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial","volume":"400","author":"Tesfaye","year":"2022","journal-title":"Lancet"},{"key":"key20221018113808326_ref1-bib2","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1186\/s13063-018-2959-y","article-title":"Multicentre, double-blind, crossover trial to identify the Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus (OPTION-DM): study protocol for a randomised controlled trial","volume":"19","author":"Selvarajah","year":"2018","journal-title":"Trials"},{"key":"key20221018113808326_ref1-bib3","volume-title":"Attribution 4.0 International (CC BY 4.0)","author":"Creative Commons"},{"key":"key20221018113808326_ref1-bib4","volume-title":"Number of People with Diabetes Reaches 4.8 Million","author":"Diabetes UK","year":"2020"},{"key":"key20221018113808326_ref1-bib5","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.2337\/dc11-1108","article-title":"Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K.","volume":"34","author":"Abbott","year":"2011","journal-title":"Diabetes Care"},{"key":"key20221018113808326_ref1-bib6","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.2337\/dc05-2228","article-title":"The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes","volume":"29","author":"Davies","year":"2006","journal-title":"Diabetes Care"},{"key":"key20221018113808326_ref1-bib7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1526-4637.2007.00347.x","article-title":"Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options","volume":"9","author":"Veves","year":"2008","journal-title":"Pain Med"},{"key":"key20221018113808326_ref1-bib8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.2337\/diacare.28.4.956","article-title":"Diabetic neuropathies: a statement by the American Diabetes Association","volume":"28","author":"Boulton","year":"2005","journal-title":"Diabetes Care"},{"key":"key20221018113808326_ref1-bib9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0168-8227(99)00112-6","article-title":"Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life","volume":"47","author":"Galer","year":"2000","journal-title":"Diabetes Res Clin Pract"},{"key":"key20221018113808326_ref1-bib10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/01.ajp.0000210910.49923.09","article-title":"Sleep impairment in patients with painful diabetic peripheral neuropathy","volume":"22","author":"Zelman","year":"2006","journal-title":"Clin J Pain"},{"key":"key20221018113808326_ref1-bib11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jpainsymman.2005.04.009","article-title":"Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep","volume":"30","author":"Gore","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"key20221018113808326_ref1-bib12","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jpain.2006.04.013","article-title":"Burden of illness in painful diabetic peripheral neuropathy: the patients\u2019 perspectives","volume":"7","author":"Gore","year":"2006","journal-title":"J Pain"},{"key":"key20221018113808326_ref1-bib13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jdiacomp.2005.09.007","article-title":"Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns","volume":"20","author":"T\u00f6lle","year":"2006","journal-title":"J Diabetes Complications"},{"key":"key20221018113808326_ref1-bib14","unstructured":"National Institute for Health and Care Excellence (NICE). Neuropathic Pain in Adults: Pharmacological Management in Non-Specialist Settings. Clinical Guideline [CG173]. London: NICE; 2013."},{"key":"key20221018113808326_ref1-bib15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008242.pub3","article-title":"Amitriptyline for neuropathic pain in adults","volume":"7","author":"Moore","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"key20221018113808326_ref1-bib16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007115.pub3","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia (review)","volume":"3","author":"Lunn","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key20221018113808326_ref1-bib17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007076.pub2","article-title":"Pregabalin for acute and chronic pain in adults","volume":"3","author":"Moore","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"key20221018113808326_ref1-bib18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007938.pub2","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults (review)","volume":"3","author":"Moore","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key20221018113808326_ref1-bib19","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.2337\/dc07-2105","article-title":"Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses","volume":"31","author":"Freeman","year":"2008","journal-title":"Diabetes Care"},{"key":"key20221018113808326_ref1-bib20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2377-8-29","article-title":"Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials","volume":"8","author":"Sultan","year":"2008","journal-title":"BMC Neurol"},{"key":"key20221018113808326_ref1-bib21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1136\/bmj.39213.565972.AE","article-title":"Effects of treatments for symptoms of painful diabetic neuropathy: systematic review","volume":"335","author":"Wong","year":"2007","journal-title":"BMJ"},{"key":"key20221018113808326_ref1-bib22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/dmrr.1225","article-title":"Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management","volume":"27","author":"Tesfaye","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"key20221018113808326_ref1-bib23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4065\/mcp.2009.0649","article-title":"Recommendations for the pharmacological management of neuropathic pain: an overview and literature update","volume":"85","author":"Dworkin","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"key20221018113808326_ref1-bib24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision [published online ahead of print]","author":"Attal","year":"2010","journal-title":"Eur J Neurol"},{"key":"key20221018113808326_ref1-bib25","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1464-5491.2009.02806.x","article-title":"Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial","volume":"26","author":"Bansal","year":"2009","journal-title":"Diabet Med"},{"key":"key20221018113808326_ref1-bib26","doi-asserted-by":"publisher","first-page":"818","DOI":"10.2337\/dc10-1793","article-title":"A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial","volume":"34","author":"Kaur","year":"2011","journal-title":"Diabetes Care"},{"key":"key20221018113808326_ref1-bib27","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.2337\/dc12-0656","article-title":"Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life","volume":"35","author":"Boyle","year":"2012","journal-title":"Diabetes Care"},{"key":"key20221018113808326_ref1-bib28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2377-9-6","article-title":"Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain","volume":"9","author":"Quilici","year":"2009","journal-title":"BMC Neurol"},{"key":"key20221018113808326_ref1-bib29","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa042580","article-title":"Morphine, gabapentin, or their combination for neuropathic pain","volume":"352","author":"Gilron","year":"2005","journal-title":"N Engl J Med"},{"key":"key20221018113808326_ref1-bib30","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1056\/NEJM200506233522520","article-title":"Morphine, gabapentin, or their combination for neuropathic pain","volume":"352","author":"Tesfaye","year":"2005","journal-title":"N Engl J Med"},{"key":"key20221018113808326_ref1-bib31","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.pain.2013.05.043","article-title":"Duloxetine and pregabalin: high-dose monotherapy or their combination? The \u2018COMBO-DN study\u2019 \u2013 a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain","volume":"154","author":"Tesfaye","year":"2013","journal-title":"Pain"},{"key":"key20221018113808326_ref1-bib32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jpain.2006.01.443","article-title":"Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain","volume":"7","author":"Wu","year":"2006","journal-title":"J Pain"},{"key":"key20221018113808326_ref1-bib33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1185\/030079908x253852","article-title":"Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK","volume":"24","author":"Beard","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"key20221018113808326_ref1-bib34","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2165\/0019053-200826120-00007","article-title":"A cost\u2013utility comparison of four first-line medications in painful diabetic neuropathy","volume":"26","author":"O\u2019Connor","year":"2008","journal-title":"PharmacoEconomics"},{"key":"key20221018113808326_ref1-bib35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.pcd.2012.03.001","article-title":"An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings","volume":"6","author":"de Salas-Cansado","year":"2012","journal-title":"Prim Care Diabetes"},{"key":"key20221018113808326_ref1-bib36","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","article-title":"Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial","volume":"280","author":"Backonja","year":"1998","journal-title":"JAMA"},{"key":"key20221018113808326_ref1-bib37","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.pain.2012.03.003","article-title":"Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations","volume":"153","author":"Dworkin","year":"2012","journal-title":"Pain"},{"key":"key20221018113808326_ref1-bib38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pain.2004.12.010","article-title":"Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)","volume":"114","author":"Bouhassira","year":"2005","journal-title":"Pain"},{"key":"key20221018113808326_ref1-bib39","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1464-5491.2009.02667.x","article-title":"Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy","volume":"26","author":"Bril","year":"2009","journal-title":"Diabet Med"},{"key":"key20221018113808326_ref1-bib40","unstructured":"Great Britain. Data Protection Act 2018. London: The Stationery Office; 2018."},{"key":"key20221018113808326_ref1-bib41","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S0895-4356(98)00081-X","article-title":"Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project","volume":"51","author":"Ware","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"key20221018113808326_ref1-bib42","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"key20221018113808326_ref1-bib43","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"key20221018113808326_ref1-bib44","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1389-9457(00)00065-4","article-title":"Validation of the Insomnia Severity Index as an outcome measure for insomnia research","volume":"2","author":"Bastien","year":"2001","journal-title":"Sleep Med"},{"key":"key20221018113808326_ref1-bib45","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"key20221018113808326_ref1-bib46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hec.3564","article-title":"Valuing health-related quality of life: an EQ-5D-5L value set for England","volume":"27","author":"Devlin","year":"2018","journal-title":"Health Econ"},{"key":"key20221018113808326_ref1-bib47","first-page":"200","volume-title":"Measuring Mental Health Needs","author":"Beecham","year":"2001"},{"key":"key20221018113808326_ref1-bib48","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.pain.2003.12.024","article-title":"Development and validation of the Neuropathic Pain Symptom Inventory","volume":"108","author":"Bouhassira","year":"2004","journal-title":"Pain"},{"key":"key20221018113808326_ref1-bib49","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.pain.2014.08.014","article-title":"The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study","volume":"155","author":"Demant","year":"2014","journal-title":"Pain"},{"key":"key20221018113808326_ref1-bib50","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/j.pain.2014.08.020","article-title":"Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study","volume":"155","author":"Bouhassira","year":"2014","journal-title":"Pain"},{"key":"key20221018113808326_ref1-bib51","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ejp.763","article-title":"Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?","volume":"20","author":"Marchettini","year":"2016","journal-title":"Eur J Pain"},{"key":"key20221018113808326_ref1-bib52","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1097\/j.pain.0000000000002130","article-title":"Stratification of patients based on the Neuropathic Pain Symptom Inventory: development and validation of a new algorithm","volume":"162","author":"Bouhassira","year":"2021","journal-title":"Pain"},{"key":"key20221018113808326_ref1-bib53","volume-title":"British National Formulary","author":"Joint Formulary Committee"},{"key":"key20221018113808326_ref1-bib54","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1177\/0962280213476379","article-title":"Estimating effect sizes for health-related quality of life outcomes","volume":"23","author":"Julious","year":"2014","journal-title":"Stat Methods Med Res"},{"key":"key20221018113808326_ref1-bib55","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain"},{"key":"key20221018113808326_ref1-bib56","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/sim.1783","article-title":"A tutorial in biostatistics: sample sizes for clinical trials with normal data","volume":"23","author":"Julious","year":"2004","journal-title":"Stat Med"},{"key":"key20221018113808326_ref1-bib57","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S0140-6736(09)61081-3","article-title":"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial","volume":"374","author":"Gilron","year":"2009","journal-title":"Lancet"},{"key":"key20221018113808326_ref1-bib58","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1080\/10543400903105406","article-title":"Last observation carried forward: a crystal ball?","volume":"19","author":"Kenward","year":"2009","journal-title":"J Biopharm Stat"},{"key":"key20221018113808326_ref1-bib59","volume-title":"Guideline on Missing Data in Confirmatory Clinical Trials","author":"European Medicines Agency","year":"2010"},{"key":"key20221018113808326_ref1-bib60","volume-title":"Statistical Analysis with Missing Data","author":"Little","year":"2019","edition":"3"},{"key":"key20221018113808326_ref1-bib61","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/sim.8569","article-title":"Sensitivity analysis for clinical trials with missing continuous outcome data using controlled multiple imputation: a practical guide","volume":"39","author":"Cro","year":"2020","journal-title":"Stat Med"},{"key":"key20221018113808326_ref1-bib62","volume-title":"Guide to the Methods of Technology Appraisal","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"key20221018113808326_ref1-bib63","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1478-7547-11-6","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"11","author":"Husereau","year":"2013","journal-title":"Cost Eff Resour Alloc"},{"key":"key20221018113808326_ref1-bib64","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"key20221018113808326_ref1-bib65","volume-title":"Position Statement on Use of the EQ-5D5L Value Set for England (Updated October 2019)","author":"National Institute for Health and Care Excellence"},{"key":"key20221018113808326_ref1-bib66","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"key20221018113808326_ref1-bib67","volume-title":"National Cost Collection for the NHS 2018\/19","author":"NHS"},{"key":"key20221018113808326_ref1-bib68","volume-title":"Unit Costs of Health and Social Care 2019","author":"Curtis","year":"2019"},{"key":"key20221018113808326_ref1-bib69","volume-title":"Podiatry Clinic Tariff","author":"The Podiatry Clinic"},{"key":"key20221018113808326_ref1-bib70","volume-title":"Podiatry Service Prices","author":"A&A Podiatrists"},{"key":"key20221018113808326_ref1-bib71","volume-title":"Treatments and Prices","author":"The Footcare Centre"},{"key":"key20221018113808326_ref1-bib72","volume-title":"NHS TCS 2018 (AfC)","author":"NHS Employers"},{"key":"key20221018113808326_ref1-bib73","volume-title":"Price List","author":"Escape Holistic Therapies"},{"key":"key20221018113808326_ref1-bib74","volume-title":"Home Massage and Aromatherapy Treatments Price Guide","author":"Holly\u2019s Holistics"},{"key":"key20221018113808326_ref1-bib75","volume-title":"Treatments and Prices","author":"Natural at Heart"},{"key":"key20221018113808326_ref1-bib76","volume-title":"Unit Costs of Health and Social Care 2020","author":"Curtis","year":"2020"},{"key":"key20221018113808326_ref1-bib77","volume-title":"Earnings and Hours Worked, All Employees: ASHE Table 1","author":"Office for National Statistics","year":"2020"},{"key":"key20221018113808326_ref1-bib78","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40273-018-0628-3","article-title":"Comparing the UK EQ-5D-3L and English EQ-5D-5L value sets","volume":"36","author":"Mulhern","year":"2018","journal-title":"PharmacoEconomics"},{"key":"key20221018113808326_ref1-bib79","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1212\/WNL.0b013e3182166ebe","article-title":"Evidence-based guideline: treatment of painful diabetic neuropathy","volume":"76","author":"Bril","year":"2011","journal-title":"Neurology"},{"key":"key20221018113808326_ref1-bib80","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1097\/j.pain.0000000000000143","article-title":"Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial","volume":"156","author":"Holbech","year":"2015","journal-title":"Pain"},{"key":"key20221018113808326_ref1-bib81","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"key20221018113808326_ref1-bib82","volume-title":"Neuropathic Pain in Adults: Pharmacological Management in Non-Specialist Settings. Clinical Guideline [CG173]","author":"National Institute for Health and Care Excellence","year":"2020"},{"key":"key20221018113808326_ref1-bib83","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008943.pub2","article-title":"Combination pharmacotherapy for the treatment of neuropathic pain in adults","volume":"7","author":"Chaparro","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key20221018113808326_ref1-bib84","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3305\/nh.2015.32.4.9605","article-title":"Normative values of EQ-5D-5L for diabetes patients from Spain","volume":"32","author":"Collado Mateo","year":"2015","journal-title":"Nutr Hosp"},{"key":"key20221018113808326_ref1-bib85","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.vhri.2015.11.003","article-title":"The EQ-5D-5L is more discriminative than the EQ-5D-3L in patients with diabetes in Singapore","volume":"9","author":"Wang","year":"2016","journal-title":"Value Health Reg Issues"},{"key":"key20221018113808326_ref1-bib86","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s11136-014-0902-6","article-title":"The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients","volume":"24","author":"Pan","year":"2015","journal-title":"Qual Life Res"},{"key":"key20221018113808326_ref1-bib87","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.neurol.2020.01.361","article-title":"Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations","volume":"176","author":"Moisset","year":"2020","journal-title":"Rev Neurol"},{"key":"key20221018113808326_ref1-bib88","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-16-S2-O1","article-title":"Good practice principles for sharing individual participant data from publicly funded clinical trials","volume":"16","author":"Smith","year":"2015","journal-title":"Trials"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2040424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/RXUO6757\/RXUO6757.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2040424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T11:52:08Z","timestamp":1692100328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/RXUO6757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":88,"journal-issue":{"issue":"39","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["10.3310\/RXUO6757"],"URL":"https:\/\/doi.org\/10.3310\/rxuo6757","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"6-2016","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"9-2021","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"3-2022","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}